- Home
- A-Z Publications
- Current Pharmaceutical Design
- Previous Issues
- Volume 26, Issue 19, 2020
Current Pharmaceutical Design - Volume 26, Issue 19, 2020
Volume 26, Issue 19, 2020
-
-
Cold Atmospheric Plasma as a Novel Therapeutic Tool for the Treatment of Brain Cancer
Background: Studies from the past few years revealed the importance of Cold Atmospheric Plasma (CAP) on various kinds of diseases, including brain cancers or glioblastoma (GBM), and hence coined a new term ‘Plasma Medicine’ in the modern world for promising therapeutic approaches. Here, we focus on the efficacy of CAP and its liquid derivatives on direct interactions or with specific nanoparticles to show pivotal roles i Read More
-
-
-
Carbon Dots as Nanotherapeutics for Biomedical Application
Authors: Eemaan N. Cohen, Pierre P.D. Kondiah, Yahya E. Choonara, Lisa C. du Toit and Viness PillayCarbon nanodots are zero-dimensional spherical allotropes of carbon and are less than 10nm in size (ranging from 2-8nm). Based on their biocompatibility, remarkable water solubility, eco- friendliness, conductivity, desirable optical properties and low toxicity, carbon dots have revolutionized the biomedical field. In addition, they have intrinsic photo-luminesce to facilitate bio-imaging, bio-sensing and theranostic Read More
-
-
-
Current Status and Challenges in Rotigotine Delivery
Rotigotine is a non-ergoline, high lipophilic dopamine agonist. It is indicated as the first-line therapy for Parkinson's disease (PD) and Restless Leg Syndrome (RLS). However, the precise mechanism of rotigotine is yet to be known. Rotigotine has similar safety and tolerability to the other oral non-ergolinic dopamine antagonists in clinical trials, which include nausea, dizziness and somnolence. Neupro® was the first marketed t Read More
-
-
-
Nose to Brain Delivery of Nanocarriers Towards Attenuation of Demented Condition
Increasing incidence of demented patients around the globe with limited FDA approved conventional therapies requires pronounced research attention for the management of the demented conditions in the growing elderly population in the developing world. Dementia of Alzheimer’s type is a neurodegenerative disorder, where conventional therapies are available for symptomatic treatment of the disease but possess seve Read More
-
-
-
Neuropsychological Disorders and their Nanocarriers
Authors: Surbhi Sharma and Shweta DangNeuropsychological disorders are now growing rapidly worldwide among the people of diverse backgrounds irrespective of age, gender, and geographical region. Such disorders not only disturb the normal life and functionality of an individual but also impact the social relationships of the patient and the people associated with them, and if not treated in time, it may also result in mortality in severe conditions. Various antip Read More
-
-
-
Recent Advances in Nanotherapeutic Interventions for the Treatment of Alzheimer’s Disease
Authors: Anmol Dogra, R.S. Narang and Jasjeet K. NarangAlzheimer’s disease (AD), with impairment of learning and memory as the common clinical manifestations, is one of the most challenging diseases affecting individuals, their families and society as a whole. The fact that its prevalence is escalating rapidly, with the total number of AD patients estimated to reach 115.4 million by 2050, has made the disease a very challenging ailment worldwide. Several biological barriers like th Read More
-
-
-
Orally Administered Nanotherapeutics For Parkinson’s Disease: An Old Delivery System Yet More Acceptable
Authors: Nidhi Aggarwal, Zufika Qamar, Saleha Rehman, Sanjula Baboota and Javed AliAs per the present global scenario, Parkinson’s disease (PD) is considered to be the second most common neurodegenerative disorder which is a keen area of interest among researchers. The conventional therapies generally employed against PD are associated with serious drawbacks including limited transport across selectively permeable BBB, hepatic metabolism, intestinal barrier, etc. This urges the need to develop Read More
-
-
-
Ligand Conjugated Targeted Nanotherapeutics for Treatment of Neurological Disorders
Background: Human brain is amongst the most complex organs in human body, and delivery of therapeutic agents across the brain is a tedious task. Existence of blood brain barrier (BBB) protects the brain from invasion of undesirable substances; therefore it hinders the transport of various drugs used for the treatment of different neurological diseases including glioma, Parkinson's disease, Alzheimer's disease, etc. To surmo Read More
-
Volumes & issues
-
Volume 31 (2025)
-
Volume 30 (2024)
-
Volume 29 (2023)
-
Volume 28 (2022)
-
Volume 27 (2021)
-
Volume 26 (2020)
- Issue 46
- Issue 45
- Issue 44
- Issue 43
- Issue 42
- Issue 41
- Issue 40
- Issue 39
- Issue 38
- Issue 37
- Issue 36
- Issue 35
- Issue 34
- Issue 33
- Issue 32
- Issue 31
- Issue 30
- Issue 29
- Issue 28
- Issue 27
- Issue 26
- Issue 25
- Issue 24
- Issue 23
- Issue 22
- Issue 21
- Issue 20
- Issue 19
- Issue 18
- Issue 17
- Issue 16
- Issue 15
- Issue 14
- Issue 13
- Issue 12
- Issue 11
- Issue 10
- Issue 9
- Issue 8
- Issue 7
- Issue 6
- Issue 5
- Issue 4
- Issue 3
- Issue 2
- Issue 1
-
Volume 25 (2019)
-
Volume 24 (2018)
-
Volume 23 (2017)
-
Volume 22 (2016)
-
Volume 21 (2015)
-
Volume 20 (2014)
-
Volume 19 (2013)
-
Volume 18 (2012)
-
Volume 17 (2011)
-
Volume 16 (2010)
-
Volume 15 (2009)
-
Volume 14 (2008)
-
Volume 13 (2007)
-
Volume 12 (2006)
-
Volume 11 (2005)
-
Volume 10 (2004)
-
Volume 9 (2003)
-
Volume 8 (2002)
-
Volume 7 (2001)
-
Volume 6 (2000)
Most Read This Month
Article
content/journals/cpd
Journal
10
5
false
en
